High-density lipoprotein and inflammation in cardiovascular disease

Translational Research

Volumn 173, Issue , 2016, Pages 7-18

  Connelly, Margery A ^a   Shalaurova, Irina ^a   Otvos, James D ^a  

^a LIPOSCIENCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LIPIDOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEOMICS; REVIEW; COMPLICATION; METABOLISM;

BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; IMMUNE SYSTEM; INFLAMMATION; LIPOPROTEINS, HDL;

EID: 84956888754     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.01.006     Document Type: Review

References (113)

1. 1 Ross, R., Glomset, J.A., Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180 (1973), 1332–1339.
2. 2 Rohatgi, A., High-density lipoprotein function measurement in human studies: focus on cholesterol efflux capacity. Prog Cardiovasc Dis 58 (2015), 32–40.
3. 3 Favari, E., Chroni, A., Tietge, U.J., et al. Cholesterol efflux and reverse cholesterol transport. Handb Exp Pharmacol 224 (2015), 181–206.
4. 4 Rothblat, G.H., Phillips, M.C., High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 21 (2010), 229–238.
5. 5 Soran, H., Hama, S., Yadav, R., et al. HDL functionality. Curr Opin Lipidol 23 (2012), 353–366.
6. 6 van der Stoep, M., Korporaal, S.J., Van Eck, M., High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovasc Res 103 (2014), 362–371.
7. 7 Zhu, X., Parks, J.S., New roles of HDL in inflammation and hematopoiesis. Annu Rev Nutr 32 (2012), 161–182.
8. 8 Mineo, C., Shaul, P.W., Novel biological functions of high-density lipoprotein cholesterol. Circ Res 111 (2012), 1079–1090.
9. 9 Rosenson, R.S., Brewer, H.B. Jr., Ansell, B., et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 128 (2013), 1256–1267.
10. 10 Karlsson, H., Kontush, A., James, R.W., Functionality of HDL: antioxidation and detoxifying effects. Handb Exp Pharmacol 224 (2015), 207–228.
11. 11 Camont, L., Lhomme, M., Rached, F., et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 33 (2013), 2715–2723.
12. 12 Mineo, C., Deguchi, H., Griffin, J.H., et al. Endothelial and antithrombotic actions of HDL. Circ Res 98 (2006), 1352–1364.
13. 13 Thomson, R., Samanovic, M., Raper, J., Activity of trypanosome lytic factor: a novel component of innate immunity. Future Microbiol 4 (2009), 789–796.
14. 14 Feingold, K.R., Grunfeld, C., Lipids: a key player in the battle between the host and microorganisms. J Lipid Res 53 (2012), 2487–2489.
15. 15 Tuteja, S., Rader, D.J., High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm. Clin Pharmacol Ther 96 (2014), 48–56.
16. 16 Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001), 2486–2497.
17. 17 Kuivenhoven, J.A., Groen, A.K., Beyond the genetics of HDL: why is HDL cholesterol inversely related to cardiovascular disease?. Handb Exp Pharmacol 224 (2015), 285–300.
18. 18 Vickers, K.C., Remaley, A.T., HDL and cholesterol: life after the divorce?. J Lipid Res 55 (2014), 4–12.
19. 19 Shah, A.S., Tan, L., Long, J.L., et al. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 54 (2013), 2575–2585.
20. 20 Kontush, A., Lindahl, M., Lhomme, M., et al. Structure of HDL: particle subclasses and molecular components. Handb Exp Pharmacol 224 (2015), 3–51.
21. 21 Vaisar, T., Pennathur, S., Green, P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117 (2007), 746–756.
22. 22 Shiflett, A.M., Bishop, J.R., Pahwa, A., et al. Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem 280 (2005), 32578–32585.
23. 23 Gordon, S.M., Deng, J., Lu, L.J., et al. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res 9 (2010), 5239–5249.
24. 24 Kontush, A., Lhomme, M., Chapman, M.J., Unraveling the complexities of the HDL lipidome. J Lipid Res 54 (2013), 2950–2963.
25. 25 Jahangiri, A., High-density lipoprotein and the acute phase response. Curr Opin Endocrinol Diabetes Obes 17 (2010), 156–160.
26. 26 Watanabe, J., Charles-Schoeman, C., Miao, Y., et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 64 (2012), 1828–1837.
27. 27 Vaisar, T., Mayer, P., Nilsson, E., et al. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 411 (2010), 972–979.
28. 28 Green, P.S., Vaisar, T., Pennathur, S., et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 118 (2008), 1259–1267.
29. 29 Alwaili, K., Bailey, D., Awan, Z., et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 1821 (2012), 405–415.
30. 30 Holzer, M., Wolf, P., Curcic, S., et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 53 (2012), 1618–1624.
31. 31 Charles-Schoeman, C., Watanabe, J., Lee, Y.Y., et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 60 (2009), 2870–2879.
32. 32 Farbstein, D., Levy, A.P., HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther 10 (2012), 353–361.
33. 33 Yasuda, T., Ishida, T., Rader, D.J., Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 74 (2010), 2263–2270.
34. 34 Sattar, N., McCarey, D.W., Capell, H., et al. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108 (2003), 2957–2963.
35. 35 Toms, T.E., Panoulas, V.F., Kitas, G.D., Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J 5 (2011), 64–75.
36. 36 Chung, C.P., Oeser, A., Raggi, P., et al. Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis. J Rheumatol 37 (2010), 1633–1638.
37. 37 Otocka-Kmiecik, A., Mikhailidis, D.P., Nicholls, S.J., et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog Lipid Res 51 (2012), 314–324.
38. 38 Khovidhunkit, W., Kim, M.S., Memon, R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45 (2004), 1169–1196.
39. 39 de la Llera Moya, M., McGillicuddy, F.C., Hinkle, C.C., et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 222 (2012), 390–394.
40. 40 Fogelman, A.M., Further evidence that high-density lipoprotein is a chameleon-like lipoprotein. Eur Heart J 36 (2015), 3017–3019.
41. 41 Mackness, B., Mackness, M., Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv Exp Med Biol 660 (2010), 143–151.
42. 42 Deakin, S., Moren, X., James, R.W., HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler Thromb Vasc Biol 27 (2007), 1146–1152.
43. 43 Huang, Y., Wu, Z., Riwanto, M., et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 123 (2013), 3815–3828.
44. 44 Zheng, L., Nukuna, B., Brennan, M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114 (2004), 529–541.
45. 45 Undurti, A., Huang, Y., Lupica, J.A., et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 284 (2009), 30825–30835.
46. 46 Riwanto, M., Rohrer, L., Roschitzki, B., et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127 (2013), 891–904.
47. 47 Vaisar, T., Tang, C., Babenko, I., et al. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res 56 (2015), 1519–1530.
48. 48 Thomas, M.J., Sorci-Thomas, M.G., SAA: a link between cholesterol efflux capacity and inflammation?. J Lipid Res 56 (2015), 1383–1385.
49. 49 G, H.B., Rao, V.S., Kakkar, V.V., Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol, 2011, 2011, 274629.
50. 50 Raterman, H.G., Levels, H., Voskuyl, A.E., et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis 72 (2013), 560–565.
51. 51 McInnes, I.B., Thompson, L., Giles, J.T., et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 74 (2013), 694–702.
52. 52 Liao, K.P., Playford, M.P., Frits, M., et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc, 4, 2015.
53. 53 Rohatgi, A., de Lemos, J.A., Shaul, P.W., HDL cholesterol efflux capacity and cardiovascular events. N Engl J Med 372 (2015), 1871–1872.
54. 54 Rosenson, R.S., Brewer, H.B. Jr., Davidson, W.S., et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125 (2012), 1905–1919.
55. 55 Corsetti, J.P., Gansevoort, R.T., Sparks, C.E., et al. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest 40 (2010), 483–489.
56. 56 Saleheen, D., Scott, R., Javad, S., et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol 3 (2015), 507–513.
57. 57 Rohatgi, A., Khera, A., Berry, J.D., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371 (2014), 2383–2393.
58. 58 Nobecourt, E., Jacqueminet, S., Hansel, B., et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48 (2005), 529–538.
59. 59 Morgantini, C., Natali, A., Boldrini, B., et al. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60 (2011), 2617–2623.
60. 60 Charles-Schoeman, C., Lee, Y.Y., Grijalva, V., et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 71 (2012), 1157–1162.
61. 61 O'Neill, F., Riwanto, M., Charakida, M., et al. Structural and functional changes in HDL with low grade and chronic inflammation. Int J Cardiol 188 (2015), 111–116.
62. 62 Ahmed, U., Tanwir, F., Association of periodontal pathogenesis and cardiovascular diseases: a literature review. Oral Health Prev Dent 13 (2015), 21–27.
63. 63 Pirillo, A., Catapano, A.L., Norata, G.D., HDL in infectious diseases and sepsis. Handb Exp Pharmacol 224 (2015), 483–508.
64. 64 Brousseau, M.E., Schaefer, E.J., Wolfe, M.L., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004), 1505–1515.
65. 65 Jafri, H., Alsheikh-Ali, A.A., Mooney, P., et al. Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD. J Clin Lipidol 3 (2009), 45–50.
66. 66 Bays, H., Giezek, H., McKenney, J.M., et al. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metab Syndr Relat Disord 10 (2012), 260–266.
67. 67 Toth, P.P., Thakker, K.M., Jiang, P., et al. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vasc Health Risk Manag 8 (2012), 39–44.
68. 68 Gauthamadasa, K., Rosales, C., Pownall, H.J., et al. Speciated human high-density lipoprotein protein proximity profiles. Biochemistry 49 (2010), 10656–10665.
69. 69 Jeyarajah, E.J., Cromwell, W.C., Otvos, J.D., Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006), 847–870.
70. 70 Kingwell, B.A., Chapman, M.J., Kontush, A., et al. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov 13 (2014), 445–464.
71. 71 Otvos, J.D., The surprising AIM-HIGH results are not surprising when viewed through a particle lens. J Clin Lipidol 5 (2011), 368–370.
72. 72 Matyus, S.P., Braun, P.J., Wolak-Dinsmore, J., et al. NMR measurement of LDL particle number using the Vantera® Clinical Analyzer. Clin Biochem 47 (2014), 203–210.
73. 73 Otvos, J.D., Mora, S., Shalaurova, I., et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 5 (2011), 105–113.
74. 74 Mora, S., Buring, J.E., Ridker, P.M., Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 129 (2014), 553–561.
75. 75 Mackey, R.H., Greenland, P., Goff, D.C. Jr., et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 60 (2012), 508–516.
76. 76 Parish, S., Offer, A., Clarke, R., et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 125 (2012), 2469–2478.
77. 77 Milionis, H., Liamis, G., Elisaf, M., Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy. Expert Opin Biol Ther 15 (2015), 287–298.
78. 78 Mora, S., Glynn, R.J., Ridker, P.M., High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 128 (2013), 1189–1197.
79. 79 McGarrah, R.W., Craig, D.M., Haynes, C., Dowdy, Z.E., Shah, S.H., Kraus, W.E., High-density lipoprotein particle concentration has a stronger inverse association with cardiovascular events than high density lipoprotein cholesterol in a coronary catheterization population. Circulation, 128, 2013, A17332.
80. 80 May, H.T., Anderson, J.L., Winegar, D.A., et al. Utility of high density lipoprotein (HDL) cholesterol, particle concentration, and size in predicting future major adverse cardiovascular events among patients undergoing angiography. J Am Coll Cardiol, 63, 2014, A1318.
81. 81 Matyus, S.P., Braun, P.J., Wolak-Dinsmore, J., et al. HDL particle number measured on the Vantera®, the first clinical NMR analyzer. Clin Biochem 48 (2015), 148–155.
82. 82 Kontush, A., HDL particle number and size as predictors of cardiovascular disease. Front Pharmacol 6 (2015), 218–223.
83. 83 Martin, S.S., Jones, S.R., Toth, P.P., High-density lipoprotein subfractions: current views and clinical practice applications. Trends Endocrinol Metab 25 (2014), 329–336.
84. 84 Rizzo, M., Otvos, J., Nikolic, D., et al. Subfractions and subpopulations of HDL: an update. Curr Med Chem 21 (2014), 2881–2891.
85. 85 Rosenson, R.S., Brewer, H.B. Jr., Chapman, M.J., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57 (2011), 392–410.
86. 86 Otvos, J.D., Collins, D., Freedman, D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006), 1556–1563.
87. 87 Otvos, J.D., Shalaurova, I., Wolak-Dinsmore, J., et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem 61 (2015), 714–723.
88. 88 Dungan, K., Binkley, P., Osei, K., GlycA is a novel marker of inflammation among non-critically ill hospitalized patients with type 2 diabetes. Inflammation 38 (2015), 1357–1363.
89. 89 Ormseth, M.J., Chung, C.P., Oeser, A.M., et al. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res Ther, 17, 2015, 117.
90. 90 Dullaart, R.P., Gruppen, E.G., Connelly, M.A., et al. A pro-inflammatory glycoprotein biomarker is associated with lower bilirubin in metabolic syndrome. Clin Biochem 48 (2015), 1045–1047.
91. 91 Dullaart, R.P., Gruppen, E.G., Connelly, M.A., et al. GlycA, a biomarker of inflammatory glycoproteins, is more closely related to the leptin/adiponectin ratio than to glucose tolerance status. Clin Biochem 48 (2015), 811–814.
92. 92 Bell, J.D., Brown, J.C., Nicholson, J.K., et al. Assignment of resonances for ‘acute-phase’ glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett 215 (1987), 311–315.
93. 93 Gruppen, E.G., Connelly, M.A., Otvos, J.D., et al. A novel protein glycan biomarker and LCAT activity in metabolic syndrome. Eur J Clin Invest, 45, 2015, 850.
94. 94 Dijk, W., Turner, G., Mackiewicz, A., Changes in glycosylation of acute-phase proteins in health and disease: occurrence, regulation and function. Glycoconj J 1 (1994), 5–14.
95. 95 Ceciliani, F., Pocacqua, V., The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr Protein Pept Sci 8 (2007), 91–108.
96. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J Proteome Res 9 (2010), 4545–4553.
97. 97 Chung, C.P., Ormseth, M.J., Connelly, M.A., et al. GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus. Lupus, 2015 [Epub ahead of print].
98. 98 Akinkuolie, A.O., Buring, J.E., Ridker, P.M., et al. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc, 3, 2014, e001221.
99. 99 Gruppen, E.G., Riphagen, I.J., Connelly, M.A., et al. GlycA, a pro-inflammatory glycoprotein biomarker, and incident cardiovascular disease: relationship with C-reactive protein and renal function. PLoS One, 10, 2015, e0139057.
100. 100 Akinkuolie, A.O., Glynn, R.J., Ridker, P.M., Mora, S., Protein glycan side-chains, rosuvastatin therapy, and incident vascular events: an analysis from the JUPITER trial. Circulation, 130, 2014, A17731.
101. 101 Muhlestein, J.B., Mays, H., Winegar, D.A., et al. GlycA and GlycB, novel NMR biomarkers of inflammation, strongly predict future cardiovascalar events, but not the presence of coronary artery disease (CAD), among patients undergoing, coronary angiography: the Intermountain Heart Collaborative Study. J Am Coll Cardiol, 63, 2014, 61389.
102. 102 Fischer, K., Kettunen, J., Wurtz, P., et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med, 11, 2014, e1001606.
103. 103 Ritchie, S.C., Wurtz, P., Nath, A.P., et al. Systems medicine links microbial inflammatory response with glycoprotein-associated mortality risk. Cell Systems 1 (2015), 293–301.
104. 104 Akinkuolie, A.O., Pradhan, A.D., Buring, J.E., et al. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 35 (2015), 1544–1550.
105. 105 Connelly, M.A., Gruppen, E.G., Wolak-Dinsmore, J., et al. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta 452 (2015), 10–17.
106. 106 Kim, K.I., Oh, S.W., Ahn, S., et al. CRP level and HDL cholesterol concentration jointly predict mortality in a Korean population. Am J Med 125 (2012), 787–795.e4.
107. 107 Zewinger, S., Drechsler, C., Kleber, M.E., et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J 36 (2015), 3007–3016.
108. 108 Festa, A., Williams, K., Hanley, A.J., et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111 (2005), 3465–3472.
109. 109 Ferrannini, E., Nannipieri, M., Williams, K., et al. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 53 (2004), 160–165.
110. 110 Drew, B.G., Rye, K.A., Duffy, S.J., et al. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 8 (2012), 237–245.
111. 111 Shalaurova, I., Connelly, M.A., Garvey, W.T., et al. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord 12 (2014), 422–429.
112. 112 Ridker, P.M., Luscher, T.F., Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 35 (2014), 1782–1791.
113. 113 Voight, B.F., Peloso, G.M., Orho-Melander, M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study. Lancet 380 (2012), 572–580.